Amplidiag® CarbaR+VRE

CE-IVD. For in vitro diagnostic use.

 

Amplidiag® CarbaR+VRE identifies clinically most relevant carbapenemase groups as well as vancomycin resistance markers in one single test.

 

This molecular diagnostic test has been designed to be a cost-effective solution for high-volume screening from pure culture samples for the diagnosis of carbapenemase-producing organisms (CPO) and vancomycin-resistant Enterococci (VRE).

 

This qualitative multiplex real-time PCR test gives results within a few hours, as opposed to days with culture-based screening methods. By allowing rapid and reliable detection of antibiotic resistances, Amplidiag CarbaR+VRE supports decisions to manage efficiently epidemiological and infection control measures and improve patient care.



  • KPC (all known variants)
  • NDM (all known variants)
  • VIM (all known variants)
  • OXA-48 (all known variants)
  • OXA-181 (all known variants)
  • IMP (all known variants)
  • ISAbaI-OXA-51, OXA-23, OXA-40, OXA58 (all known variants)
  • vanA (vanA gene)
  • vanB (vanB gene)
  • Sample material: DNA extracted from pure culture
  • Product format: Multiplex real-time PCR kit
  • Result analysis and reporting: Automated with Amplidiag Analyzer software
  • DNA extracted from pure culture sample
  • Rapidly screen the presence of CPO and VRE
  • All targets detected and reported in a single test, from a single sample
  • Suited for high-volume screening
  • Automated results analysis with Amplidiag Analyzer software
  • Option for workflow automation with Amplidiag Easy
  • Effectively guides infection control measures and reduces epidemics

If you are interested in the effective screening of key antimicrobial resistances from pure culture samples, contact sales@mobidiag.com for more information and test use pos




About carbapenem and vancomycin resistance

Carbapenems are often referred to as the “last resort” antibiotics, as there are few to none effective therapies for infectious organisms resistant to carbapenems. Carbapenemases are enzymes that hydrolyze carbapenem antibiotics, and are produced by organisms referred to as carbapenem-resistant organisms, most often Enterobacteriaceae. Many carbapenemases hydrolyze not only carbapenems, but almost all β-lactamase antibiotics. While some carbapenemase encoding genes reside in chromosomes and spread only clonally, many plasmid-residing carbapenemase genes have been described. These mobile, easily transferrable resistance genes are a major threat for hospitals struggling with outbreaks of multi-resistant bacteria globally.

Enterococci are naturally multi-resistant bacteria that are part of human intestinal flora. While generally harmless, Enterococci are opportunistic pathogens known to cause serious infections, especially in hospital environments. In recent years, the problem of E. faecium and E. faecalis, the two most significant enterococcal pathogens, has become more severe due to the acquisition of vanA and vanB conveyed glycopeptide resistance, including vancomycin resistance. During the last twenty years, the spread of these plasmid mediated glycopeptide resistance genes has been alarming, making VREs a major threat for healthcare units.